Oxford Immune Algorithmics

About Oxford Immune Algorithmics

Oxford Immune Algorithmics (OIA) is a health technology company, spun out from the University of Oxford, developing a platform for predictive and personalized medicine. Founded in 2018 by Dr. Hector Zenil, OIA aims to shift healthcare from a reactive, population-based model to a proactive and individualized system. Dr. Zenil, who has a background in computer science and computational biology from institutions like Oxford, Cambridge, and the Karolinska Institute, established the company to bridge the gap between academic research and clinical practice. His work includes contributions to the technology behind AI assistants like Siri and Alexa.

The company's flagship product is Algocyte®, a Health-as-a-Service (HaaS) platform that provides an end-to-end solution for remote health monitoring. The system combines a portable, at-home blood testing device, the Mobile Health Station (MHS), with a powerful AI engine. The MHS allows users to perform various blood tests, starting with a Complete Blood Count (CBC), using a small blood sample and receive immediate results. The device utilizes spectroscopy, light microscopy, and immunofluorescence to analyze samples.

The data is uploaded to a secure cloud platform where AI algorithms analyze it, along with other clinical and lifestyle information, to create a personalized health baseline or 'digital twin' for each user. This enables the system to detect deviations from an individual's normal state, providing early warnings to clinicians for potential health issues. The AI provides explainable insights, supporting clinical decision-making rather than operating as a 'black box'. The business model focuses on deploying this platform in clinical pathways for remote surveillance of chronic diseases, with plans to expand into general practitioner support and direct-to-consumer health monitoring.